Clarithromycin

Chemical formula: C₃₈H₆₉NO₁₃  Molecular mass: 747.953 g/mol  PubChem compound: 84029

Therapeutic indications

Clarithromycin is indicated for:

Acute exacerbation of chronic bronchitis, community acquired pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Acute exacerbation of chronic bronchitis
Community acquired pneumonia
and additionally Clarithromycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute bacterial sinusitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute bacterial sinusitis and additionally Clarithromycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Streptococcal pharyngitis and tonsillitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Streptococcal sore throat
Streptococcal tonsillitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Skin and soft tissue infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Soft tissue infection and additionally Clarithromycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Clarithromycin is contraindicated in the following cases:

Hypersensitivity to macrolide antibiotic drugs

Allergy to macrolide

Ergot alkaloids

at least one of
Ergot alkaloids
Ergot alkaloids
Ergot alkaloids

Astemizole, cisapride, pimozide, terfenadine

at least one of
Astemizole
Cisapride
Pimozide
Terfenadine

QT prolongation, ventricular cardiac arrhythmia, torsades de pointes

at least one of
Long QT syndrome
Prolonged QT interval
Ventricular arrhythmia

Ticagrelor, ranolazine

at least one of
Ticagrelor
Ranolazine

Lovastatin, simvastatin

at least one of
Lovastatin
Simvastatin

Colchicine

Colchicine

Hypokalemia

Hypokalemia

Severe hepatic failure in combination with renal impairment

Hepatic failure stage IV and additionally Renal failure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CLARITHROMYCIN Film-coated tablets
Summary of Product Characteristics (SPC) 2018: CLARITHROMYCIN Powder for concentrate for solution for infusion
Summary of Product Characteristics (SPC) 2021: KLERIMED Film coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈